Lv2
158 积分 2024-10-10 加入
Physiologically Based Pharmacokinetic Modeling and Allometric Scaling in Pediatric Drug Development: Where Do We Draw the Line?
15小时前
待确认
A panel of biomarkers for disease severity in atopic dermatitis
5天前
已完结
Industry Perspective on First‐in‐Human and Clinical Pharmacology Strategies to Support Clinical Development of T‐Cell Engaging Bispecific Antibodies for Cancer Therapy
6天前
已完结
Identification of oncology pharmacokinetic drivers through in vitro experiments and computational modeling
9天前
已完结
Effect of Food (Low and High Fat) on Pharmacokinetics of FCN-159, a Selective MEK Inhibitor, in Healthy Chinese Males
14天前
已完结
Remibrutinib, a Novel Bruton Tyrosine Kinase Inhibitor, Exhibits Improved Target Selectivity and Potency in Vitro
1个月前
已完结
The Metabolism and Disposition of Brepocitinib in Humans and Characterization of the Formation Mechanism of an Aminopyridine Metabolite
1个月前
已关闭
Pharmacokinetics of tofacitinib, a janus kinase inhibitor, in patients with impaired renal function and end‐stage renal disease
1个月前
已完结
Using Quantitative Approaches to Optimize Dosages for New Combinations and Subsequent Indications for Oncology Drugs
1个月前
已完结
Use of the Child-Pugh score in anticancer drug dosing decision making: proceed with caution – Authors' reply
2个月前
已完结
皖公网安备34019202002308
